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Background: In Parkinson’s disease (PD), alpha-synuclein (AS) aggregates occur frequently in peripheral
autonomic nervous system (pANS). Their presence in asymptomatic subjects suggests incidental Lewy-
body disease (iLBD) that is thought to reﬂect pre-clinical PD. Cardiac involvement has been detected
in post-mortem studies in both, PD and also in iLBD. In vivo documentation of cardiac AS pathology is
lacking.
Objective: To prospectively assess the presence of AS aggregates in epicardial fat tissue from living
subjects without parkinsonism undergoing elective cardiac surgery.
Material and methods: Epicardial fat tissue obtained during cardiac surgery from 91 subjects was studied
by histology and immunohistochemistry. Areas more likely to contain pANS elements were selected. PD-
related motor and non-motor symptoms (NMS) were assessed immediately before or after surgery.
Results: Small autonomic nerves, ganglia and/or tyrosine-hydroxylase positive ﬁbres were identiﬁed in
epicardial fat in each of the 91 subjects (62 male/29 female, mean age 67 years). AS aggregates were
detected in 7 subjects (7.7%), and were more frequent in those aged above 70 years. In AS-positive
subjects constipation and acting dreams were signiﬁcantly more frequent than in the AS-negative ones.
Conclusion: AS aggregates occur in epicardial pANS in subjects without parkinsonism, suggesting the
diagnosis of iLBD. The presence in some of these subjects of non-motor symptoms such as acting dreams
and constipation known to occur in premotor PD supports this interpretation. Adequate follow-up of the
subjects in this study will indicate the time, if any, to progression to motor PD.
 2012 Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Movement Disorders Unit,
ospital Clínic de Barcelona, c/
75414; fax: þ34 93 2275783.
ript.
s under CC BY-NC-ND license.1. Introduction
The presence of intraneuronal aggregates of the presynaptic
protein alpha-synuclein (AS) in Lewy-bodies and neurites consti-
tutes the pathological hallmark of Parkinson’s disease (PD). Their
presence in the peripheral autonomic nervous system (pANS) has
Table 1
Demographic characteristics of study subjects.
Variable Total n ¼ 91 AS (þ) n ¼ 7 AS () n ¼ 84 P-value
Age, years
(mean  SD)
67 (11.08) 70.7 (12.8) 66.7 (10.95) 0.197
Gender male/female 62/29 3/4 59/25 0.203
BMI (kg/m2)
(mean  SD)
27.9 (4.47) 25.9 (4.99) 28.1 (4.40) 0.265
HBP n (%) 58/89 (65.2) 3/7 (42.9) 55/82(67.1) 0.188
DM n (%) 25/89 (28.1) 0/7 25/82(30.5) 0.09
Hyperlipidemia
n (%)
46/88 (52.3) 3/7 (42.9) 43/81 (53.1) 0.449
Smoking n (%) 34/87 (46.2) 2/6(33.3) 32/81(39.5) 0.564
Heart attack n (%) 18/88 (20.5) 0/7 18/81 (22.2) 0.189
Heart disease
Valvular n (%) 43/86 (50) 4/7 (57.1) 39/79 (49.4) 0.438
Ischaemic n (%) 23/86 (26.7) 1/7 (14.3) 22/79 (27.8) 0.431
Valvular þ ischaemic
n (%)
18/86 (20.9) 2/7 (28.6) 16/79 (20.3) 0.420
Others n (%) 2/86 (2.4) 0/7 2/79 (2.6) 0.851
Neurological
complications n (%)
5/64 (7.8) 0/7 5/58 (8.6) 0.99
Other complications
Renal n (%) 7/64 (10.9) 0/5 7/59 (11.9) 0.99
Respiratory n (%) 6/64 (9.4) 1/6 (16.7) 5/58 (8.6) 0.46
Cardiac n (%) 18/64 (28.1) 1/6 (16.7) 17/58(29.3) 0.667
Surgical n (%) 15/64 (23.4) 1/6 (16.7) 14/58(24.1) 0.99
Death n (%) 5/91 (5.5) 0/7 5/84 (6) 0.99
Abbreviations: BMI: body mass index; HBP: high blood pressure; DM: diabetes
mellitus.
P-value: ManneWhitney test and two-tailed Fisher’s exact test as appropriated.
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disorders (LBD) in post-mortem [1e4] and in vivo studies [5,6].
There is increasing evidence that in PD, before the substantia
nigra degenerates and parkinsonism appears, deposits of abnormal
AS occur in lower brainstem areas and central olfactory pathways
[7]. These extranigral lesions are thought to constitute the neural
substrate of what is considered “premotor PD” [8] and, in post-
mortem studies, to represent incidental Lewy-body disease (iLBD).
Although it is unclear whether iLBD always evolves to motor PD, it
is considered on the bases of pathological, inmunohistochemical
and biochemical data [9,10], that affected subjects would have had
a higher risk to develop classical motor PD [11].
Cardiovascular dysautonomic symptoms including orthostatic
hypotension and abnormalities in ReR-interval [12] have been the
focus of recent attention in PD. Of great interest are imaging studies
with 123I-metaiodobenzylguanidine (MIBG) that have documented
changes indicative of cardiac postganglionic sympathetic dener-
vation in most patients with PD. At what time in the natural history
of PD do these abnormalities occur is unclear but pathological and
imaging studies suggest that it may occur in the early [13], even
premotor phase of PD [14e18].
We have assessed the presence of AS aggregates in epicardial fat
in living subjects undergoing cardiac surgery in order to investigate
involvement of cardiac pANS in subjects without parkinsonism. The
presence of such AS aggregates would support early cardiac
involvement in LBD and suggest that these subjects are in a stage of
premotor PD.2. Material and methods
Unselected patients without clinically manifest motor symptoms of PD and with
cardiac disease undergoing elective cardiac operations at the Department of
Cardiovascular Surgery, Hospital Clinic, Barcelona (CAM, EQ) between January 2009
and June 2011 were enrolled in this study. All individuals were appropriately
informed about the study and gave their written consent. The project has been
approved by the Institutional Ethical Committee.2.1. General demographic characteristics
Recorded characteristics of participants included age, gender and cardiovascular
risk factors such as high blood pressure, diabetes mellitus, obesity (measured by
body mass index BMI), smoking, and type of heart disease (mostly ischaemic,
valvular or both). Potential post-surgical complications were recorded, including
neurological (post-surgical delirium/confusion, seizures), cardiac (arrhythmia, low
cardiac output requiring circulatory support, pericardial effusion), renal (acute renal
insufﬁciency), pulmonary (postoperative respiratory insufﬁciency requiring pro-
longed mechanical ventilation, pneumonia, pneumothorax), and surgical compli-
cations (e.g. infection, thrombosis, bleeding) as well as fatal events (death).2.2. Clinical evaluation
Patients were examined by a neurologist from the Movement Disorders Unit of
the Hospital Clinic Barcelona (ET, JN, SR) focusing on motor and non-motor features
of Parkinson’s disease. Most patients were visited before the surgical procedure to
avoid potentially post-surgical confounders. In cases where it was not possible due
to patient’s state, evaluation was performed as early as possible after the surgical
procedure. Neurologists were blinded to pathological results.
Examination consisted on a daily activities evaluation (using uniﬁed Parkinson’s
Disease Rating Scale e UPDRS II scale), motor exploration (UPDRS III scale) and
application of a reduced version of a questionnaire of non-motor problems in Par-
kinson’s disease (NMSQuest) [19]. Eleven non-motor symptoms-related items from
the NMSQuest were chosen which included one related to hyposmia, four to auto-
nomic dysfunction (gastrointestinal symptoms, genitourinary symptoms, and
cardiovascular dysfunction), three related to cognitive problems, and three to sleep
disturbances (for details see also Table 1).
In the ﬁrst 20 subjects studied (pilot phase of the study) no information on non-
motor symptoms was obtained. In eight additional cases clinical data were not
available (fatal event before clinical evaluation in two patients, six patients could not
be evaluated before nor after surgery because they were transferred to another
hospital).2.3. Surgical procedure
During cardiac surgery, small fragments of epicardial fat tissue (0.5e2 cm in
diameter) were obtained from the areas more likely to contain autonomic nervous
tissue according to previous literature [20] and to our own experience in prelimi-
nary post-mortem studies (unpublished data). We did not expect to cause any
additional risk to patients nor complicate the surgical procedure due to sampling.
The areas from where samples were taken are routinely approached in cardiac
surgery for different purposes like placement of cavitary vents, access to epicardial
coronary arteries and routine cannulations. These areas included fat tissue from the
following regions: cavoatrial junction, interatrial groove (WatersoneSondergaard
groove), right coronary artery along the acute cardiac margin, left anterior
descending coronary artery along the interventricular septum, and fatty tissue
surrounding the aortic root and ascending aorta and right superior pulmonary vein.
Samples were taken before performing the epicardial (coronary bypass) or intra-
cardiac procedure (valve replacement/repair) with the use of cardiopulmonary
bypass, and were immediately placed in 4.5% buffered formaldehyde solution.
Special attention was paid to possible complications related to the site of fat
sampling. Therefore care was taken to avoid potential bleeding from sampling sites
with exhaustive regional check before closure of the chest.
2.4. Pathological studies
Formalin-ﬁxed samples were embedded in parafﬁn. Five micrometer thick
sections from each block were stained with haematoxylineeosin for standard
histopathological evaluation and by immunohistochemistry using antibodies
directed against tyrosine-hydroxylase (mouse monoclonal, clone TH-16, dilution
1:3000, SigmaeAldrich, St. Louis, MO, USA), alpha-synuclein (mouse monoclonal,
clone KM51, dilution 1:500, Novocastra, Newcastle upon Tyne, UK), and anti-
phosphorylated alpha-synuclein (mouse monoclonal, phosphorylated at Ser 129,
dilution 1:1000, Wako Pure Chemical Industries LTD, Japan) at the Neurological
Tissue Bank of the Biobanc-Hospital Clinic-IDIBAPS. Tissue section pretreatment for
antigen retrieval was performed by boiling sections in 10 mM citrate buffer at pH6
for 10 min.
Detection of immunostaining was performed using the Envision kit, and dia-
minobenzidine was used as chromogen.
On histological examination, presence of autonomic nervous tissue and detec-
tion of pathological AS and phospho-AS (pAS) aggregates in these structures were
assessed (EG). In cases with positive AS aggregates, consensus evaluation was per-
formed on amultiheadedmicroscope by ET, JN, CAM, and EG. To assess degeneration
in those cardiac nerves with AS aggregates we performed immunohistochemistry
using anti-TH, anti-AS and anti-pAS antibodies on serial sections in selected cases.
In addition, to investigate whether potential AS aggregation in our living
subjects could be related to underlying heart disease, we analysed post-mortem
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autopsy group without known cardiologic or neurologic clinical symptoms, except
one case with mild cognitive impairment without parkinsonism.
We used brain tissue from a brain donor with Parkinson’s disease as positive
control for AS and pAS immunoreactivity, a paravertebral sympathetic ganglion as
positive control for TH-immunoreactivity, and omitted the primary antibody for
control of antibody speciﬁcity.
2.5. Statistical analyses
Statistical analyses were performed with the Statistical Package for Social
Sciences (SPSS) (PASW Statistics Version 18.00). Comparisons between groups were
performed using ManneWhitney test and two-tailed Fisher’s exact test as appro-
priated. A p-value lower than 0.05 was considered statistically signiﬁcant.
3. Results
3.1. Study subjects
Ninety-one adult patients (older than 18 years of age) were
enrolled in the study. Demographic data of the study participants
are shown in Table 1. Seventy-one percent were male. Mean age
was 67 years (range 31e84). Cardiovascular risk factors and type of
cardiac disease for which the patients were listed for an operation
are presented in Table 1.
None of the patients were thought to have parkinsonism on
neurological examination (Table 2). One patient with the highest
UPDRS III (12) had severe generalised arthrosis. Forty patients had
symptoms known to occur in premotor PD: hyposmia in 20%,
constipation in 11.5% and acting dreams in 12.9%.
Post-surgery, neither anatomical nor functional cardiac
complications occurred that could be related to the sampling of fat
tissue.
3.2. Autonomic nervous tissue in epicardial fat
In all but one individual, small nerve ﬁbres and/or autonomic
ganglia were detected in three or four of the total epicardial fat
tissue samples obtained in each case (Fig. 1A, C). Fat from the
cavoatrial junction and interatrial groove were the regions whereTable 2
Results of motor and non-motor evaluations.
Clinical variables Total n ¼ 91 AS (þ) n ¼ 7 AS () n ¼ 84 P-value
UPDRS II median
(range)
0 (0e2) 0 (0e0) 0 (0e2) 0.26
UPDRS III median
(range)
1 (0e12)c 0 (0e2) 1 (0e12) 0.15
Hyposmia n (%)a 12/60 (20) 1/6 (16.7) 11/54 (20.4) 0.99
Constipation n (%) 7/61 (11.5) 3/7 (42.9) 4/54 (7.4) 0.03b
Urinary urgency n (%) 19/61 (31.1) 1/7 (14.3) 18/54 (33.3) 0.42
Impaired memory n (%) 11/61 (18) 3/7 (42.9) 8/54 (14.8) 0.10
Lack of interest n (%) 3/54 (5.6) 1/4 (25) 2/50 (4) 0.21
Hallucinations n (%) 4/55 (7.3) 2/6 (33.3) 2/49 (4.1) 0.06
Clinical orthostatic
hypotension n (%)
8/55 (14.5) 1/6 (16.7) 7/49 (14.3) 0.99
Problems in getting
asleep n (%)
18/59 (30.5) 1/6 (16.7) 17/53 (32.1) 0.66
Vivid dreams n (%) 11/62 (17.7) 3/7 (42.9) 8/55 (14.5) 0.10
Acting dreams n (%) 8/62 (12.9) 3/7 (42.9) 5/55 (9.1) 0.04b
Swelling of legs n (%) 3/49 (6.1) 1/4 (25) 2/45 (4.4) 0.23
Any non-motor
symptom n (%)
40/62 (64.5) 6/7 (85.7) 34/55 (61.8) 0.41
AS (þ) subjects with alpha-synuclein aggregates; AS () subjects without alpha-
synuclein aggregates.
a Percentages are represented in relation to the total of subjects with a valid
response in each item.
b Statistically signiﬁcant differences between AS (þ) and AS () groups. Man-
neWhitney test and two-tailed Fisher’s exact test as appropriated.
c One patient with UPDRS III of 12 had severe arthrosis.larger ganglia and thicker, partly tyrosine-hydroxylase positive
nerve ﬁbres were observed (Fig. 1D).
3.3. Alpha-synuclein aggregates
In seven out of 91 subjects (7.7%), abnormal AS/pAS aggregates
were detected in at least two samples from the same individual.
These aggregates were observed predominantly along nerve ﬁbres
(Fig. 1F, J) and in between neurons of autonomic ganglia (Fig. 1E).
Here, in addition, isolated neurons showed diffuse dot-like peri-
karyal immunoreactivity. This type of immunoreactivity has been
described by some authors as an early step in the morphogenesis of
Lewy-bodies in the CNS [21]. Similarly to what has been described
in post-mortem brains, phospho-AS showed more diffuse, dot-like
immunoreactivity along nerve ﬁbres than observed by KM51
antibody (Fig. 1G, K, N). pAS is considered a more speciﬁc and
sensitive marker of LB-related pathology, probably representing
a pathological change that precedes LB-related neuronal degener-
ation [22]. We observed that a proportion of cases containing AS
aggregates in epicardial nerve ﬁbres showed reduced TH-
immunoreactivity (Fig. 1H, L) in some nerve ﬁbres when
compared to cases without AS aggregates (Fig. 1D), although this
was not a consistent ﬁnding. No quantitative assessment was per-
formed due to the small sample sizes.
3.4. AS aggregates and clinical correlation
Among the seven patients with abnormal AS aggregates in
epicardial fat tissue, the most common reported non-motor
symptoms were constipation in three, impaired memory in three,
and vivid dreams and acting dreams in three that clinically sug-
gested REM sleep behaviour disorder (RBD). The youngest patient
(45 years) had no symptoms suggestive of premotor PD (Table 3).
One of the patients with constipation, hallucinations, RBD and
memory complaints had the highest amount of AS aggregates in
epicardial fat tissue (case 5).
3.5 Post-mortem cohort
We studied post-mortem cardiac tissue of 14 consecutive
autopsy cases without known cardiac disease (43% male; mean age
68 years, range 46e85). We found AS/pAS positive aggregates in
cardiac autonomic nerves in one subject (7%) who had mild
cognitive impairment without parkinsonism according to clinical
records. No detailed analysis of AS distribution in the brain was
available in this case.
4. Discussion
Our results show that abnormal, phosphorylated AS aggregates
can be detected in vivo in neurons and nerve ﬁbres of the epicardial
ANS in subjects without parkinsonism. AS inclusions have been
described in post-mortem studies in the cardiac pANS of patients
with PD [3,13] and also in subjects without parkinsonism or
dementia thought to have iLBD [13,23e25]. They are also analogous
to those described in vivo in abdominopelvic plexus in asymp-
tomatic subjects [26]. In this study subjects with incidental AS-
positive aggregates were thought to have pre-clinical PD or pre-
clinical dementia with Lewy-bodies (DLB) like those with iLBD.
ILBD is a term usually applied post-mortem, but that could also be
applied in vivo to subjects without parkinsonism but documented
AS in the nervous system. The percentage of our non-parkinsonian
study subjects with incidental AS aggregates in epicardial pANS
(7.7%) is not dissimilar from the percentages of iLBD encountered in
post-mortem [1,11,13] and in vivo studies [26], with a tendency to
Fig. 1. Alpha-synuclein aggregates in epicardial fat tissue. First row (AeD) illustrates histological ﬁndings in normal appearing epicardial fat tissue in a case without AS aggregates.
Haematoxylineeosin stain of epicardial fat tissue containing small autonomic ganglia (A) and small nerves (C). Some nerve ﬁbres are strongly immunoreactive for tyrosine-
hydroxylase (TH) (D) whereas in autonomic ganglia, only few neurons and delicate nerve ﬁbres show TH-immunoreactivity (B). Middle and lower rows (EeN) depict AS-posi-
tive cases. AS aggregates are detected in autonomic ganglia (E) as ﬁne elongated processes between satellite and Schwann cells, as well as in small nerves (F) as relatively compact
aggregates. Using anti-phosphorylated AS (pAS) antibodies, more diffuse and dot-like immunoreactivity along nerve ﬁbres can be detected in some larger ﬁbres (G). This can also be
appreciated, in adjacent tissue sections, in small nerve ﬁbres (IeJeK and MeN), where more diffuse pAS than AS immunoreactivity is observed. In addition, a reduction of TH-
immunoreactivity was observed in some larger ﬁbres (H) and in smaller nerve ﬁbres (L) containing AS/pAS aggregates (J, K), but this was not a regular ﬁnding. Scale bars: A, B:
50 mm; CeN: 20 mm.
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and 9.1% in the 9th) as also observed in previous studies [11,13,24].
We believe that our study subjects bearing AS aggregates in
epicardial pANS could be considered iLBD and as such to suffer from
premotor PD. These subjects could also be considered to representTable 3
Clinical characteristics of subjects with AS aggregates in epicardial fat tissue.
Case 1 2 3 4 5 6 7
Age 77 78 62 75 80 45 78
Gender f m f m f f m
Number of AS (þ)
samples/total samples
3/6 2/5 3/5 3/6 3/5 3/6 3/5
UPDRS II n.a. 0 0 0 n.a. 0 0
UPDRS III 0 1 0 0 n.a. 0 2
Hyposmia No Yes No No n.a. No No
Constipation Yes Yes No No Yes No No
Urinary urgency No No No Yes No No No
Memory No Yes No Yes Yes No No
Lack of interest n.a. n.a. No Yes n.a. No No
Hallucinations n.a. No No Yes Yes No No
Clinical orthostatism No No No Yes n.a. No No
Getting asleep problems No n.a. Yes No No No No
Vivid dreams No Yes No Yes Yes No No
Acting dreams No Yes No Yes Yes No No
Swelling of legs n.a. n.a. No No n.a. No Yes
f: Female, m: male, n.a.: not available.pre-clinical DLB, as might be suggested in one of our study subject
who suffered from hallucinations, RBD andmemory complaints but
did not fulﬁll criteria of dementia at the moment of clinical
assessment.
Cardiovascular dysautonomic symptoms are a focus of attention
in PD but the clinical correlation of cardiac sympathetic denerva-
tion is still unclear. Although cardiovascular examinations are
frequently normal even in advanced cases and in those with MIBG
abnormalities, retrospective studies had found a higher prevalence
of diastolic hypertension, angina, arrhythmia, and heart infarct
during the decade before onset of motor symptoms when
compared with a control group [27]. Consistent data are even less
available for iLBD. Retrospective analysis of post-mortem conﬁrmed
iLBD cases showed no signiﬁcant differences compared to controls
concerning high blood pressure, coronary artery disease, peripheral
vascular disease [10,28] or cardiac arrhythmia, as a possible
consequence of sympathetic denervation [9]. Also Beach et al found
that supraventricular arrhythmias and hypertension were common
in iLBD cases but they were also common in control cases [10].
Even if we can not exclude the possibility that in our study
patients AS aggregates in cardiac autonomic nerves might be
related to hypoxic damage, the presence of these aggregates in
patients with both, ischaemic and non-ischaemic cardiac pathology
and in post-mortem cases without cardiac disease suggests that
probably ischaemia is not a major AS aggregation trigger in these
cases. Furthermore, other studies have evaluated the presence of AS
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infarction and observed no increase of cardiac AS pathology [13].
A fraction of cases with AS aggregates showed reduced TH-
immunoreactivity in some nerve ﬁbres. To draw ﬁrm conclusions
concerning the presence and/or severity of nerve ﬁbre degenera-
tion in these small tissue samples is difﬁcult. On the one hand, the
number and thickness of epicardial nerve ﬁbres is variable and
there is a mixture of sympathetic and parasympathetic ﬁbres.
Furthermore, reduced TH-immunoreactivity was not a consistent
ﬁnding, and its assessment is especially difﬁcult in small tissue
samples and remains subjective.
As we have studied only cardiac ANS, our results do not clarify
whether heart involvement is the only site of AS pathology in our
study subjects. The presence in some of our AS-positive study
subjects of symptoms that are known to antedate in some cases
motor PD such as acting dreams (suggestive of RBD [29,30]),
hyposmia and constipation, could suggest that central nervous
system and/or other sites of the ANS are already affected.
In summary, we have shown that abnormal AS aggregates are
present in epicardial pANS obtained during cardiac surgery in
a substantial number of living subjects without parkinsonism. We
believe that these subjects could represent instances of pre-clinical
LBD, the same way as subjects without parkinsonism shown to
have Lewy-bodies in the central nervous system are thought to
have iLBD, a prelude for the development of the motor syndrome of
PD. Extensive NMS evaluation including objective assessment of
smell and cardiac dysautonomia and follow-up studies are in
progress to assess the possible development of both, non-motor
and motor PD-related symptoms in the subjects of our study.Conﬂicts of interest
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